FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-1.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.41 0.00 (0.34%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
FGEN 0.41 -0.01(-1.78%)
Will FGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FGEN
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Other News for FGEN
FibroGen CFO, Chief Medical Officer to leave
FibroGen CFO, CMO to leave company by year's end
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
FibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside Potential